Angiotensin Converting Enzyme

Type: Keyphrase
Name: Angiotensin Converting Enzyme
First reported Sep 26 2014 - Updated Sep 26 2014 - 1 reports

Maternal BMI and Control of Diabetes in Young Patients

Abhary, S., Hewitt, A.W., Burdon, K.P., & Craig, J.E. (2009). A systematic metaanalysis of genetic association studies for diabetic retinopathy. Diabetes, 58 (9), 2137–2147.Blumberg, S.J., Bialostosky, K, Hamilton, W.L., & Briefel, R.R. (1999). The effectiveness ... [Published General Medicine eJournal - Sep 26 2014]
First reported Sep 23 2014 - Updated Sep 23 2014 - 1 reports

Stop the Bleeding

Endoscopy is one of the most common approaches for examining the airway.Photo: Anne M. EberhardtAs prevalent as EIPH is, we still don't fully understand this potentially performance-limiting condition; here's what scientists are trying to find out.E xercise-induced ... [Published TheHorse.com - Sep 23 2014]
First reported Sep 20 2014 - Updated Sep 20 2014 - 1 reports

Foods that treat kidney disease, boost renal function

Continued from last weekMoreover, a study published in the Journal of Agricultural and Food Chemistry in June 2013 found that a compound present in asparagus, 2”-hydroxynicotianamine, could inhibit angiotensin-converting enzyme activity in the kidneys, ... [Published Daily Newswatch - Sep 20 2014]
Entities: Kidney, Watermelon, Allicin
First reported Sep 17 2014 - Updated Sep 17 2014 - 1 reports

Study Modification: Angioedema in response to angiotensin-converting enzyme inhibitor

AUTHOR: Pare GSTUDY DATE: July 8, 2013TITLE: Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. ... [Published National Human Genome Research Institute - Sep 17 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Hibiscus tea is shown to lower blood pressure

In the United States, high blood pressure is the most common medical condition.It has been estimated that one out of three Americans have high blood pressure. Untreated high blood pressure significantly increases the risk of stroke, heart attack and sudden ... [Published Chicago Daily Herald - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Blood Pressure-Lowering Peptides from Neo-Fermented Buckwheat Sprouts: A New Approach to Estimating ACE-Inhibitory Activity

by Masahiro Koyama, Seiji Hattori, Yoshihiko Amano, Masanori Watanabe, Kozo NakamuraNeo-fermented buckwheat sprouts (neo-FBS) contain angiotensin-converting enzyme (ACE) inhibitors and vasodilators with blood pressure-lowering (BPL) properties in spontaneously ... [Published Plosone.org - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

PARADIGM-HF: Is It Applicable to US Patients?

Hello. This is Ileana Piña, Associate Chief of Cardiology at Montefiore Einstein Hospital and Medical Center in the Bronx, New York. Today I am in the beautiful city of Barcelona at the European Society of Cardiology (ESC) Congress. More than 30,000 individuals ... [Published General Medicine eJournal - Sep 12 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Renin-Angiotensin System Blockade and Worsening Renal Function in Heart Failure An Unfinished Story ∗

Up to one-half of patients with heart failure (HF) have preserved ejection fraction (HFpEF). Although treatment of patients with HF and reduced ejection fraction (HFrEF) is well established and based on evidence from multiple randomized clinical trials, ... [Published Journal of the American College of Cardiology - Sep 08 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

Example of Trial Design Data Relevant for All Stakeholders

BioCentury  has lead article this week “Betting Big on Hearts” by Emily Cukier-Meisner, Senior Writer, discussing a breakthrough drug for cardiovascular disease developed by Novartis. LCZ696 for heart failure will replace ACE inhibitors widely, so ... [Published eClinical Trends - Sep 08 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

Angiotensin-converting–enzyme (ACE) inhibitors have been the cornerstone of the treatment for heart failure and a reduced ejection fraction for nearly 25 years, since enalapril was shown to reduce the risk of death in two trials.1,2 Long-term treatment ... [Published NEJM Articles Most Widely Covered in the Press - Sep 03 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Incentivised case finding and other stories . . .

At its best, general practice can be a wonderful human interchange, carried out in short encounters over many years. At its worst, it can be like the dysfunctional processes described in a qualitative study ( BMJ Open 2014;4:e005146, doi:10.1136/bmjopen-2014-005146) ... [Published British Medical Journal - Sep 03 2014]
First reported Sep 02 2014 - Updated Sep 03 2014 - 2 reports

Novartis may have game-changing drug

Share this article: Novartis is poised to change the way heart-failure patients are treated, if weekend reaction to data surrounding its experimental drug LCZ696 is any indication. The company released data at the European Society of Cardiology Congress ... [Published Medical Marketing And Media - Sep 03 2014]

Quotes

"Based on the data generated from our Phase 1b studies in pancreatic and non-small cell lung cancer we have identified a dosing regimen with impressive anti-tumor activity and an acceptable safety profile. We have confidence that these data enable the advancement of both programs into planned randomized Phase 2 studies in pancreatic cancer and NSCLC.  Results from our Phase 1b demcizumab program not only signal the potential safety and anti-tumor activity for this drug, but also provide encouragement for the potential of an anti-cancer stem cell hypothesis" said Paul J Hastings, Chairman and Chief Executive Officer
...investigator for the Phase 1b demcizumab clinical study, in the "Gastrointestinal tumours, non-colorectal" discussion session in a poster titled: "A Phase 1b Study of the Anti-Cancer Stem Cell Agent Demcizumab (DEM) & Gemcitabine (GEM) +/- Paclitaxel Protein Bound Particles (nab-paclitaxel) in Patients with Pancreatic Cancer" (#616PD)
...placental barrier and can cause fetal toxicity," said Rachel Meyers PhPh D , Vice President of Research and RNAi Lead Development (RLD) at Alnylam. "The new pre-clinical data demonstrate that an RNAi therapeutic targeting AGT ameliorates the clinical sequelae of preeclampsia and improves outcomes for the fetus in an established transgenic rat model. This treatment approach has the potential for selective delivery to the pregnant mother without fetal drug exposure, as our study has confirmed undetectable siRNA levels in the fetus. We look forward to advancing ALN-AGT as a highly innovative approach for the management of HDP and preeclampsia."
...thrombosis or embolism, or can be duedue to a hemorrhage. According to the World Health Organization, stroke is a "neurological deficit of cerebrovascular cause that persists beyond 24 hours or is interrupted by death within 24 hours." Persistence of symptoms beyond 24 hours separates stroke from Transient Ischemic Attack (TIA), in which symptoms persist for less than 24 hours

More Content

All (75) | News (63) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Kidney Fibrosis Treatment Market: Global Indust... [Published SBWire - 21 hours ago]
OncoMed's Demcizumab Phase 1b Clinical Trials S... [Published Virtual Strategy Magazine - Sep 28 2014]
OncoMed's Demcizumab Phase 1b Clinical Trials S... [Published Industrial Info Financials - Sep 28 2014]
OncoMed's Demcizumab Phase 1b Clinical Trials S... [Published GlobeNewswire - Sep 28 2014]
Man presents with unilateral intermediate uveitis [Published Orthopedics Today - Sep 27 2014]
Cardiac and Renal Effects of Atrasentan in Comb... [Published Sexual Development - Sep 26 2014]
Maternal BMI and Control of Diabetes in Young P... [Published General Medicine eJournal - Sep 26 2014]
Alnylam Pharmaceuticals : Broadens Pipeline wit... [Published 4 Traders - Sep 24 2014]
Treatment of stroke using isolated placental cells [Published PharmCast - Sep 23 2014]
Stop the Bleeding [Published TheHorse.com - Sep 23 2014]
Inactivation of AMPK Mediates High Phosphate-In... [Published Sexual Development - Sep 23 2014]
Peripheral sea-fan retinal neovascularization a... [Published 7thSpace - Sep 23 2014]
When you learn you have high blood pressure [Published WTOP - Sep 22 2014]
Foods that treat kidney disease, boost renal fu... [Published Daily Newswatch - Sep 20 2014]
MacPractice MD MU Achieves ONC HIT 2014 Edition... [Published Ask.com - Sep 18 2014]
Integrated Natriuretic Peptide and Echo-Guided ... [Published Theheart.org - Sep 18 2014]
Study Modification: Angioedema in response to a... [Published National Human Genome Research Institute - Sep 17 2014]
SFRP5 Correlates With Obesity and Metabolic Syn... [Published General Medicine eJournal - Sep 17 2014]
When You Learn You Have High Blood Pressure [Published PR Web via Yahoo! - Sep 16 2014]
Vitamin D Deficiency Aggravates Chronic Kidney ... [Published Plosone.org - Sep 15 2014]
Blood Pressure-Lowering Peptides from Neo-Ferme... [Published Plosone.org - Sep 15 2014]
Hibiscus tea is shown to lower blood pressure [Published Chicago Daily Herald - Sep 15 2014]
Amgen Presents Analyses Of Phase 3 Ivabradine D... [Published Scottrade - Sep 15 2014]
Inhibiting Neprilysin Is Good for the Heart: Wh... [Published Alzheimer Research Forum - Sep 13 2014]
A Rapid-Fire Review of Four Big Trials From ESC... [Published Theheart.org - Sep 12 2014]
PARADIGM-HF: Is It Applicable to US Patients? [Published General Medicine eJournal - Sep 12 2014]
Parkinson's Disease Pharmacogenomics: New Findings [Published General Medicine eJournal - Sep 12 2014]
New Guidance for Managing Sickle Cell Disease [Published PT Community - Sep 10 2014]
FDA Advisors Say ‘No’ to Nebivolol/ Valsartan C... [Published PT Community - Sep 10 2014]
Renin-Angiotensin System Blockade and Worsening... [Published Journal of the American College of Cardiology - Sep 08 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Example of Trial Design Data Relevant for All S... [Published eClinical Trends - Sep 08 2014]
BioCentury  has lead article this week “Betting Big on Hearts” by Emily Cukier-Meisner, Senior Writer, discussing a breakthrough drug for cardiovascular disease developed by Novartis. LCZ696 for heart failure will replace ACE inhibitors widely, so ...
Sacubitril - Valsartan, a "New Threshold of Hop... [Published Health Care Renewal - Sep 03 2014]
Summer must be over, because the next new blockbuster drug appears to be here.  At the end of August, the media heralded the results of a study of a new product for congestive heart failure (CHF) from Novartis. Novartis' New "Game Changer" The New York ...
Angiotensin–Neprilysin Inhibition versus Enalap... [Published NEJM Articles Most Widely Covered in the Press - Sep 03 2014]
Angiotensin-converting–enzyme (ACE) inhibitors have been the cornerstone of the treatment for heart failure and a reduced ejection fraction for nearly 25 years, since enalapril was shown to reduce the risk of death in two trials.1,2 Long-term treatment ...
Angiotensin–Neprilysin Inhibition versus Enalap... [Published The New England Journal of Medicine: Cardiology - Aug 30 2014]
Angiotensin-converting–enzyme (ACE) inhibitors have been the cornerstone of the treatment for heart failure and a reduced ejection fraction for nearly 25 years, since enalapril was shown to reduce the risk of death in two trials. Long-term treatment with ...
Could statins help treat Ebola? [Published AMERICAblog News| A great nation deserves the t ... - Aug 18 2014]
In an article in the New York Times , two physicians propose using drugs that are currently available to treat Ebola. Ebola causes a derangement in endothelial cells (cells lining blood vessels), and this can lead to decreased ability of the patient’s ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.